Maternal and Neonatal Outcomes in Infected Pregnant Women with Coronavirus: A Systematic Review

Document Type : Review Article

Authors

1 Assistant Professor, Health Reproductive Research Center, Sari Branch, Islamic Azad University, Sari, Iran

2 Graduated, Psychiatry and Behavioral Science Research Center, Manzandaran University of Medical Science, Sari, Iran

3 Graduated, Psychiatry and Behavioral Science Center, Manzandaran University of Medical Science, Sari, Iran

4 MSc student of Psychology, Department of Psychology, Faculty of Humanities, Islamic Azad University, Sari, Iran

5 Assistant Professor, Department of Reproductive Health, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran

6 Lecturer, Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Background & aim: Novel coronavirusease 2019 (Covid-19) started in China and caused unexplained pneumonia. The risk of adverse pregnancy outcomes increase in respiratory viral infection during pregnancy. This systematic review was performed to investigate the maternal and neonatal outcomes in pregnant women infected with Covid-19.
Methods: In this systematic review, the international databases (PubMed, Cochrane Library, Web of Science, Scopus, Embase, PsycINFO, Google scholar) as well as national databases (SID and Magiran) were searched to find out the articles published from 1 September 2020 to 30  April 2021 regarding maternal and neonatal outcomes in pregnant women infected with Covid-19. Keywords were selected based on Mesh (“Pregnancy”, “Gravidity”, “Delivery”, “Infant”, “Newborn”, “Neonate”, “Outcome”, “Complication”, “Abortion”, “Obstetric Labor, Premature”, “Cesarean Section”, “Fetal Death”, “Infant, Premature”, “Coronavirus Infection”, “COVIDK19”). The full texts of articles were reviewed by two independent reviewers and the relevant data was extracted.
Results: 20 studies including 78 pregnant women entered in this review. All women were at third trimester of pregnancy except 2 cases who were less than 28 weeks. The most prevalent clinical symptoms were fever, cough and sore throat. The most common maternal outcomes were intrauterine distress, rupture of membranes and preterm delivery. Most infants delivered by cesarean section. The most common neonatal complications were prematurity, small for gestational age, fetal distress, low birth weight and bacterial pneumonia.
Conclusion: In this systematic review, we found some evidence to suggest that COVID-19 pneumonia causes negative maternal and neonatal outcomes in pregnant women infected with Covid-19. 

Keywords


Introduction

Covid-19 started in a wet market in Wuhan, China, however it may not be the only source of this infection. In December 2019, 41 cases of unexplained pneumonia were reported in Wuhan.

This virus is a single-stranded and has 29891 nucleotides in size and encoding 9860 amino acids. Many countries have recorded the infected cases; there was no enough experience in diagnosing and managing the COVID-19. It has a very powerful pathogenicity and transmissibility (1). Now this virus is spreading in different regions, countries and continents (2). Coronavirus causes respiratory and GI tract complications in animals and human (3).

WHO (World Health Organization) has reported the pandemic status of vovid-19 on 11th March 2020 (4).

The risk of adverse pregnancy outcomes increases in respiratory viral infection during pregnancy (5). The partial immune suppression in pregnant women makes them to be vulnerable against COVID-19. They experience immunologic and physiologic changes and might be more susceptible to viral respiratory infection(6).

Managing such pregnancy is very complicated as the infection has potential adverse effect on the mother and neonate (4). Researchers reported some risks of preterm delivery (7),  PROM (premature rupture of membrane) and fetal distress when it  occurs at third trimester. There is no evidence suggesting COVID-19 increases the risk of abortion, also many physicians have fear of congenital infection and tetragenocity of this virus and they would decide pregnancy termination. Of course, data and information about pregnancy outcome in infected mothers  is not enough yet(2).    

There is no enough evidence of vertical transmission of virus. It is still unknown if it transmits through vaginal delivery. However neonatal infection can occur after birth by close contact with infected mothers (4). 

The latest studies have shown that there is no evidence for transmission of this virus through uterus. Infants who were born with identified cases of COVID-19 with no presence of this infection in cord blood and placenta, but the swabs test were positive 36 hours after birth, therefore they may be infected by droplets and contacts. Of course, this conclusion needs more research and requires more evidence (1). Although, it is yet unknown that virus shedding occurs vaginally or increases the risk of miscarriage or stillbirth (2, 8).

MERS-CoV is viral respiratory illness that is new to human and is associated with high rate of mortality (9, 10). Many studies showed adverse pregnancy outcome regarding pregnant women infected with this virus such as; maternal mortality, stillbirth, spontaneous abortion, preterm delivery, death, fetal distress, LBW (low birth weight), premature rupture of membrane (3, 5, 7, 9, 11-17). Also, high fever in early stage of pregnancy can increase the risk of certain birth defects (6).

On the other hand, some studies have shown the acceleration of some complications such as death, still birth, preeclampsia, intra uterine fetal distress in the infected pregnant women (9, 18, 19). Some researchers have reported 42% prevalence of preterm delivery in infected pregnant women, but there is no evidence regarding fetal growth or placenta pathology (20).

Now, the number of studies reporting the infected pregnancy with covid-19 is not enough to do comparative analysis on pregnancy results (4).

Physiological and immunological changes during pregnancy are the results of shift form cell-mediated to hormonal-mediated immunity and may end to sever pneumonia in pregnancy. The outcomes of pregnancy are different in the studies and it may relate to the stage of pregnancy, maternal age, the use of  drug (steroid or antiviral therapy) and potential differences in immune responses (11).

The immune response of pregnant women might change during pregnancy and postpartum, shifting from a pro-inflammatory to anti-inflammatory state. Also, we have some hormonal effects on immune system during pregnancy, for example; an increased level of progesterone is associated with several anti-inflammatory effects. Studies have shown an association of estrogen with suppression of inflammation as well as pro-inflammatory effects (21).

This systematic review study was performed with aim to determine the maternal and neonatal outcomes during pregnancy in pregnant women infected with COVID-19.

Materials and Methods

In this systematic review study, the international databases (PubMed, Cochrane Library, Web of Sciences, Scopus, Embase, and PsycINFO), national databases (SID and Magiran), and Google Scholar were searched by two independent reviewers from 1 September 2020 to 30 April 2021. Papers were selected with using the keywords of: “Pregnancy”, “Gravidity”, “Delivery”, “Infant”, “Newborn”, “Neonate”, “Outcome”, “Complication”, “Abortion”, “Obstetric Labor, Premature”, “Cesarean Section”, “Fetal Death”, “Infant, Premature”, “SARS COV 2”, “Coronavirus Infection”, and “COVID-19”. All papers were entered in EndNote X9 software to identifyduplications. In this study, there was no language restriction. Papers were searched manually among the relevant studies. The steps of article search were shown in Figure 1.  

The inclusion criteria in this study were; all papers about COVID-19 during pregnancy, and the lack of full access of articles. Also, the studies with irrelevant reports and review articles were excluded from the study.

The quality assessment of this study was done by two authors individually using the Newcastle-Ottawa Scale (NOS) checklist and scoring system to evaluate the quality of the case report studies. Newcastle-Ottawa Scale (NOS) checklist was used to evaluate the quality of cross-sectional, case control and cohort studies and this scale divided the articles in terms of selection process (in 4 sections including: sample explicitness, sample size, non-response and measurement tools), comparability (one section includes: investigation of confounders and other influencing factors) and results (from two Aspect: evaluates the result and statistical tests). According to the Newcastle Ottawa scale, articles are rated from zero (weakest study) to 10 (strongest study). In order to preserve the data, studies with a score lower than the mean score (less than a score of 4) were considered to be of lower quality. The checklist consists of three sections: selection, comparability exposure, or outcome (22) . The Scoring system was designed by Kanthraj et al, and was used to evaluate the quality of the case report studies. It includes five subcategories of goal reporting, diagnostic criteria, clinical techniques and methods, and symptom reporting, factors related to clinical existence, and the authors' conclusions (23). The quality was assessed and classified as low, medium and high.

Due to time constriction, two people (MZ, NN), conducted the search, we had searched the literature independently and read all full text, also all papers were blinded by M Gh. Disagreements were resolved by third author (ST). Evidence level was recorded blindly. Data were extracted including; demographic data, maternal imaging- diagnostic testing- outcome and perinatal and neonatal outcomes and neonatal diagnostic test.

Results

The search in databases of PubMed, Google scholar and other database selected 87, 7280 and 12 abstracts, respectively. After screening all abstracts, 124 papers were excluded due to duplication, 7185 papers were excluded because they were not about pregnant women or human or were in-vitro studies.  70 relevant studies were identified and all full texts were reviewed; finally 20 papers were included in this study (Fig.1)

Data regarding the number of women, maternal age, gestational age, source of infection, ICU admission, CT-chest, CX-Ray, antiviral therapy   were summarized in Table 1. Total number of women in the included papers was 1 to 16 (total number: 78). The maternal age was 22 to 40 years old. All women were at third trimester except 2 cases who were less than 28 weeks. Some of the infected women had a history of contact with infected people. Two cases had ICU admission. CT-chest, CX-Ray and antiviral therapy had been done in the cases. 

Data regarding the symptoms, time interval between the onset of symptoms until delivery, maternal outcome, type of delivery, die or survive and maternal real time PCR have been shown in Table 2.

The most common clinical symptoms were fever, cough and sore throat. The time interval between symptoms until delivery was 1 to 13 daysThe most common maternal outcomes were intrauterine distress, PROM and preterm delivery. The most infants had been delivered by cesarean section. 

Some information about fetal outcomes was presented in Table 3. Majority of infants was male. The most common neonatal complications were prematurity, small for gestational age, fetal distress, low birth weight and bacterial pneumonia. One infant died. Some neonates had abnormal chest radiography. The neonatal complications were fever, rapid heart rate, rash, vomiting, shortness of breath and thrombocytopenia. Most of them were singleton. The birth weight was 1520 to 3820 gr. All of them had good Apgar score and negative PCR.

   Discussion

A novel coronavirus (2019-nCoV) was diagnosed in December 2019 in infected patients with severe pneumonia. The pregnant women were more susceptible to this infection (24).

In the present study, the most common neonatal complications were prematurity, small for gestational age, fetal distress, low birth weight and bacterial pneumonia. Different pregnancy outcomes have been reported in infected pregnant women with H1N1 and SARS. A study on 12 pregnant women infected by SARS in Hong Kong had reported that 50% required ICU administration, 33% needed mechanical ventilation, 57% had spontaneous abortion (women infected in first trimester) and 80% had preterm delivery (11). Also, some neonates had abnormal chest radiography. The neonatal complications were fever, rapid heart rate, rash, vomiting, shortness of breath and thrombocytopenia. Hao Hong reported that among 9 infants, four had fever, two mild upper respiratory, one asymptomatic and two had no information on symptoms (25). Regarding the source of neonatal infection, Schwartz and coworkers believed that infection can be acquired during vaginal delivery or breastfeeding, but it would be highly unusual for respiratory virus; also fetal infection will potentially transport through aerosols produced by other resource such as; coughing from mother, relatives or healthcare workers or other source in the hospital environment (5). Neonatal morbidity was more marked due to prematurity.

To date, no evidence has been derived on whether pregnancy is sensitive situation regarding  COVID-19 (26). However, the immunological changes during pregnancy can cause the increased risk of illness and death from influenza (27). According to the data collected on the 1957 to 1958 influenza pandemic and the 2009 H1N1 influenza pandemic, the risk of contracting viral pneumonia was significantly higher in pregnant women than in other individuals (11, 28). During pregnancy, physiologically, the diaphragm moves upward, decreases pulmonary residual and expiratory reserve volumes, increases airway conductivity, and decreases total lung resistance (29). These conditions can elevate oxygen demand and possibly cause critical closing pressure, thereby placing women at more risk of respiratory problems (30). Additionally, the fetus has low tolerance for hypoxemia and acidosis, which can thus stimulate preterm labor after mid-pregnancy (29). The researchers showed that high rates of miscarriage, and neonatal prematurity can be traced to the contraction of viral pneumonia disorders, such as influenza A, H1N1 infection, … (31, 32). It is recommended that all pregnant women exposed to contact with a person infected with SARS-Cov2 be carefully examined. Assess pregnant women for fever and symptoms of respiratory infection, receive intensive care, use of experimental antibiotics, and research to design Dedicated nanoparticles that carry drugs, vaccines, or any effective drug that can target the mother's disease without fear of side effects on the fetus can help reduce the complications of Quid 19 in the pregnant mother and her fetus. Maternal and neonatal health are important health indicators. We can use the information of this article to plan health care for them in COVID-19.

Conclusion

In this study, we found some evidence to suggest that COVID-19 pneumonia causes negative maternal and neonatal outcomes in pregnant women infected with Covid-19. Future studies are needed to collect more robust data to further validate or substantiate these findings, better understand the pathophysiologic pathways that explain these associations and identify effective strategies to prevent adverse outcomes in pregnant people with COVID-19.

Acknowledgements

The authors would like to thank the editors and the anonymous reviewers for their insightful comments on this study.

Conflicts of interest

Authors declared no conflicts of interest.

1.   Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): A Chinese perspective. Journal of medical virology. 2020; 92(6): 639-644.
2.   Liang H, Acharya G. Novel corona virus disease (COVID‐19) in pregnancy: What clinical recommendations to follow. Acta obstetricia et gynecologica Scandinavica. 2020; 99(4): 439-442.
3.   Chen Y, Peng H, Wang L, Zhao Y, Zeng L, Gao H, et al. Infants born to mothers with a new coronavirus (COVID-19). Frontiers in pediatrics. 2020; 8: 104.
4.   Sahu KK, Lal A, Mishra AK. COVID‐2019 and Pregnancy: a plea for transparent reporting of all cases. Acta Obstetricia et Gynecologica Scandinavica. 2020; 99(7): 951.
5.   Swartz D, Graham A. Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses. 2020; 12(2): 194.
6.   Control CfD, Prevention. Frequently asked questions and answers: coronavirus disease 2019 (COVID-19) and pregnancy. Accessed; 2020.
7.   Khan S, Peng L, Siddique R, Nabi G. Nawsherwan; Xue, M.; Liu, J.; Han, G. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infection Control & Hospital Epidemiology. 2020; 41(6): 748-750.
8.   Iwata-Yoshikawa N, Fukushi S, Fukuma A, Suzuki T, Takeda M, Tashiro M, et al. No susceptibility of neonatal and adult rats against the Middle East respiratory syndrome coronavirus. Japanese journal of infectious diseases. 2016: 1-27. DOI: 10.7883/yoken.JJID.2015.589
9.   Assiri A, Abedi GR, Al Masri M, Bin Saeed A, Gerber SI, Watson JT. Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clinical Infectious Diseases. 2016; 63(7): 951-953.
10. Racelis S, de los Reyes VC, Sucaldito MN, Deveraturda I, Roca JB, Tayag E. Contact tracing the first Middle East respiratory syndrome case in the Philippines, February 2015. Western Pacific surveillance and response journal. 2015; 6(3): 3.
11. Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle East Respiratory Syndrome coronavirus (MERS‐CoV) on pregnancy and perinatal outcome. BMC infectious diseases. 2016; 16(1): 1-4.
12. Jeong SY, Sung SI, Sung J-H, Ahn SY, Kang E-S, Chang YS, et al. MERS-CoV infection in a pregnant woman in Korea. Journal of Korean medical science. 2017; 32(10): 1717-1720.
13. Payne DC, Iblan I, Alqasrawi S, Al Nsour M, Rha B, Tohme RA, et al. Stillbirth during infection with Middle East respiratory syndrome coronavirus. The Journal of infectious diseases. 2014; 209(12): 1870-1872.
14. Qiao J. What are the risks of COVID-19 infection in pregnant women? The Lancet. 2020; 395(10226): 760-762.
15. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. American journal of obstetrics and gynecology. 2020; 222(5): 415-426.
16. Uddin SI, Englund JA, Kuypers JY, Chu HY, Steinhoff MC, Khatry SK, et al. Burden and risk factors for coronavirus infections in infants in rural Nepal. Clinical Infectious Diseases. 2018; 67(10): 1507-1514.
17. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. Clinical infectious diseases. 2020; 10: 1-3.
18. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature. 2019; 52: 501-503.
19. Liu W, Wang Q, Zhang Q, Chen L, Chen J, Zhang B, et al. Coronavirus disease 2019 (COVID-19) during pregnancy: a case series. 2020: 1-28.
20. Mullins E, Evans D, Viner R, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound in Obstetrics & Gynecology. 2020; 55(5): 586-592.
21. Vasylyeva O. Pregnancy and COVID-19, a brief review. International Journal of Integrative Pediatrics and Environmental Medicine. 2020; 5: 8-13.
22. Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World Journal of Meta-Analysis. 2017; 5(4) :80-84.
23. Kanthraj G, Srinivas C. Journal club: screen, select, probe & evaluate. Indian Journal of Dermatology, Venereology & Leprology. 2005;71(6): 435-440.
24. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Translational pediatrics. 2020; 9(1): 51.
25. Hong H, Wang Y, Chung H-T, Chen C-J. Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatrics & Neonatology. 2020; 61(2): 131-132.
26. Hussein J. COVID-19: What implications for sexual and reproductive health and rights globally?: Taylor & Francis; 2020; 28(1): 1-3.
27. Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerging infectious diseases. 2008; 14(1): 95.
28. Rasmussen SA, Jamieson DJ. Influenza and pregnancy: No time for complacency. Obstetrics & Gynecology. 2019; 133(1): 23-26.
29. Cunningham F, Leveno K, Bloom S, Spong CY, Dashe J. Williams obstetrics, 24e: Mcgraw-hill New York, NY, USA; 2014.
30. Hamzehgardeshi Z, Yazdani F, Rezaei M, Kiani Z. COVID-19 as a Threat to Sexual and Reproductive Health. Iranian Journal of Public Health. 2020; 49(1): 136-137.
31. Wong S, Chow K, De Swiet M. Severe acute respiratory syndrome and pregnancy. International Journal of Obstetrics & Gynaecology. 2003; 110(7): 641.
32. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. American journal of obstetrics and gynecology. 2004; 191(1): 292-297.
33. Zhang L, Jiang Y, Wei M, Cheng BH, Zhou XC, Li J, et al. Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province. Zhonghua Fu Chan Ke Za Zhi. 2020; 55(3): 166-171.
34. Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, et al. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study. Clinical infectious diseases. 2020; 71(16): 2035-2041.
35. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. The Journal of infection. 2020: 1-2.